Final trade time, Tim. If you don't like Baba, JD. com has not rallied as much and is cheaper.Karen, yes. So, our little discussion of Nova Nordisk makes me think, well, really, I think it has bottomed out. So, Nova Nordisk, that's my final trade.Stephen, rates are going lower. Avis budget, that's a tailwind for them. C A R G, welcome back.Peter, well, thank you. Peter Frampton is a fan of the show. He's watching right now. He's very upset.Oh, man. Wins. ...

Final trade time, Tim. >> If you don't like Baba, JD. com has not rallied as much and is cheaper.>> Karen, >> yes. So, our little discussion of Nova Nordisk makes me think, well, really, I think it has bottomed out. So, Nova Nordisk, that's my final trade.>> Stephen, >> rates are going lower. Avis budget, that's a tailwind for them. C A R >> G, welcome back.>> Peter, well, thank you. Peter Frampton is a fan of the show. He's watching right now. He's very upset.Oh, man. Wins. ...

Results from a real-world survey suggest that semaglutide for weight management (Wegovy®) helped suppress food noise – unwanted and intrusive thoughts about food – in addition to its established effect on weight loss1The number of people who reported experiencing constant thoughts about food throughout the day declined by 46% after starting treatment with Wegovy®1The majority of respondents reported improved mental health (64%) and healthier habits (80%) while taking Wegovy®1 Bagsværd, Denmark, 16 September ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Novo Nordisk A/S regarding a class action lawsuit due to allegations of misleading statements about the company's growth potential and subsequent stock price decline [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Novo Nordisk provided overly positive statements while concealing material adverse facts about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to its branded alternatives [3]. - The company overstated its capability to penetrate the GLP-1 market, which led to inflated expectations among investors [3]. Stock Performance - Following the announcement on July 29, 2025, that Novo would lower its sales and profit outlook due to "lowered growth expectations for the second half of 2025," the stock price fell dramatically from $69.00 per share to $53.94 per share, a decline of approximately 21.83% in one day [3]. Class Action Details - The class period for the lawsuit is from May 7, 2025, to July 28, 2025, and shareholders are encouraged to register for participation by September 30, 2025 [4]. - There is no cost or obligation for shareholders to participate in the case, and they will receive updates through a portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights and ensuring companies adhere to responsible business practices [5].

Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing ! There is a free trial and a special discount of 10% for you. Join us today!I wrote my first bullish article on Novo Nordisk A/S ( NVO ) back on December 20, 2024. I argued that NVO was punished just for the short term, and I saw itDaniel Sereda is chief investment analyst at a family office whose investments span continents and diverse ass ...

Now you can get access to the latest and highest-quality analysis of recent Wall Street buying and selling ideas with just one subscription to Beyond the Wall Investing ! There is a free trial and a special discount of 10% for you. Join us today!I wrote my first bullish article on Novo Nordisk A/S ( NVO ) back on December 20, 2024. I argued that NVO was punished just for the short term, and I saw itDaniel Sereda is chief investment analyst at a family office whose investments span continents and diverse ass ...

Clinical trial results that showed the treatment reduced cardiovascular death, heart attack and stroke by 14% compared with placebo. ...

每经AI快讯，9月15日，诺和诺德现涨超2%。 ...

Core Viewpoint - Novo Nordisk's Semaglutide shows improved weight loss results when the dosage is tripled, achieving an average weight reduction of 19%, but still falls short compared to Eli Lilly's Tirzepatide, which achieves a 22.5% reduction [1][3][4] Group 1: Clinical Trial Results - In recent clinical trials, Semaglutide was tested at a dosage of 7.2 mg, compared to the approved maximum of 2.4 mg, resulting in a 19% average weight loss after 72 weeks, while the standard dosage group lost 16% and the placebo group lost only 4% [3][4] - The STEP-UP trial, involving approximately 1,400 obese adults, indicated that nearly half of the participants on the 7.2 mg dosage lost over 20% of their body weight, with one-third losing at least 25% [6] Group 2: Market Position and Challenges - Despite the new high-dose option, Semaglutide's efficacy remains below that of Eli Lilly's Tirzepatide, which has seen significant price increases in some regions, suggesting that a competitively priced 7.2 mg Semaglutide could be a more affordable alternative [4] - Novo Nordisk faces market challenges, including a 60% decline in stock price over the past year, loss of market share to Eli Lilly, and a recent announcement of a plan to lay off 9,000 employees [4] Group 3: Safety and Side Effects - The increase in dosage correlates with a rise in side effects, with approximately 71% of participants on the 7.2 mg dosage experiencing gastrointestinal symptoms, compared to 61% in the standard dosage group [6] - Over 20% of high-dose group patients reported sensory abnormalities, which may require dosage adjustments [6]

Core Insights - Novo Nordisk's Semaglutide shows significant weight loss effects when the dosage is increased to 7.2 mg, with an average weight loss of 19% over 72 weeks compared to 16% for the standard 2.4 mg dosage [1][4] - Despite the promising results, Semaglutide's efficacy still lags behind Eli Lilly's Tirzepatide, which achieved an average weight loss of 22.5% at its highest approved dosage [1][2] Group 1: Clinical Trial Results - The recent trials tested a higher dosage of Semaglutide (7.2 mg) against the standard 2.4 mg, revealing a notable increase in weight loss among participants [1][4] - In the larger STEP-UP trial, nearly half of the participants on the 7.2 mg dosage lost over 20% of their body weight, while one-third lost at least 25% [4] - The smaller trial for obese patients with type 2 diabetes showed a weight loss of 13% for the high-dose group compared to 10% for the standard dose and 4% for the placebo group [4] Group 2: Market Position and Challenges - The new high-dose option is seen as clinically meaningful, especially if priced competitively against Eli Lilly's Tirzepatide, which has seen price increases in some regions [2] - Novo Nordisk faces significant market challenges, including a 60% drop in stock price over the past year and loss of market share to Eli Lilly and generic competitors [2] - The company has recently undergone leadership changes, including a new CEO and plans to lay off 9,000 employees [2] Group 3: Safety and Side Effects - The increase in dosage correlates with a rise in side effects, with 71% of participants on the 7.2 mg dosage experiencing gastrointestinal symptoms, compared to 61% in the standard dosage group [4] - Over 20% of high-dose participants reported sensory abnormalities, which may require dosage adjustments [4] - Health indicators such as waist circumference, blood pressure, cholesterol, and blood sugar levels improved across both trials [4]